176.51 +1.67 (0.96%)
After hours: 6:54PM EST
The world grapples with the expected tug-of-war between wealthy and poorer nations over vaccine supplies, paving the way for U.S. adversaries.
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.
In this Motley Fool Live video, recorded on Feb. 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss how Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and others are faring, how they plan to deal with new variants, and what all of this means for revenue. Corinne Cardina: There has been a lot of different research about which vaccines, how they're holding up against different variants.